HK1210036A1 - Aminoisoquinoline derivatives as protein kinase inhibitors - Google Patents

Aminoisoquinoline derivatives as protein kinase inhibitors Download PDF

Info

Publication number
HK1210036A1
HK1210036A1 HK15110877.0A HK15110877A HK1210036A1 HK 1210036 A1 HK1210036 A1 HK 1210036A1 HK 15110877 A HK15110877 A HK 15110877A HK 1210036 A1 HK1210036 A1 HK 1210036A1
Authority
HK
Hong Kong
Prior art keywords
hydrogen
pharmaceutically acceptable
halogen
solvate
prodrug
Prior art date
Application number
HK15110877.0A
Other languages
English (en)
Chinese (zh)
Inventor
張民生
张民生
劉東
刘�东
陸標
陆标
Original Assignee
永恒生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 永恒生物科技公司 filed Critical 永恒生物科技公司
Publication of HK1210036A1 publication Critical patent/HK1210036A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15110877.0A 2012-09-14 2013-09-12 Aminoisoquinoline derivatives as protein kinase inhibitors HK1210036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701155P 2012-09-14 2012-09-14
US61/701,155 2012-09-14
PCT/US2013/059362 WO2014043296A1 (en) 2012-09-14 2013-09-12 Aminoisoquinoline derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1210036A1 true HK1210036A1 (en) 2016-04-15

Family

ID=50278663

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110877.0A HK1210036A1 (en) 2012-09-14 2013-09-12 Aminoisoquinoline derivatives as protein kinase inhibitors

Country Status (12)

Country Link
US (1) US20160257676A1 (de)
EP (1) EP2895166A4 (de)
JP (1) JP2015528503A (de)
KR (1) KR20150054833A (de)
CN (1) CN104703599A (de)
AU (1) AU2013315528A1 (de)
BR (1) BR112015005562A2 (de)
CA (1) CA2883386A1 (de)
HK (1) HK1210036A1 (de)
MX (1) MX2015003196A (de)
RU (1) RU2015113597A (de)
WO (1) WO2014043296A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018122746A1 (en) * 2016-12-28 2018-07-05 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
EP3601259B1 (de) 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isochinoline als inhibitoren von hpk1
EP3684772B1 (de) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclische iminopyrimidinderivate als kinaseinhibitoren
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
WO2024097953A1 (en) * 2022-11-04 2024-05-10 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2963332D1 (en) * 1978-05-26 1982-09-02 Lepetit Spa Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EA026115B1 (ru) * 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение

Also Published As

Publication number Publication date
EP2895166A1 (de) 2015-07-22
US20160257676A1 (en) 2016-09-08
RU2015113597A (ru) 2016-11-10
CA2883386A1 (en) 2014-03-20
CN104703599A (zh) 2015-06-10
MX2015003196A (es) 2015-07-06
AU2013315528A1 (en) 2015-03-12
WO2014043296A1 (en) 2014-03-20
BR112015005562A2 (pt) 2017-08-08
EP2895166A4 (de) 2016-03-16
JP2015528503A (ja) 2015-09-28
KR20150054833A (ko) 2015-05-20

Similar Documents

Publication Publication Date Title
HK1210036A1 (en) Aminoisoquinoline derivatives as protein kinase inhibitors
TWI671301B (zh) 作為PARP抑制劑的4H-吡唑並[1,5-α]苯並咪唑化合物的類似物
WO2020249079A1 (zh) 一种shp2磷酸酶变构抑制剂
WO2020094104A1 (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
KR102412035B1 (ko) TGF-βRI 억제제인 벤조트리아졸에서 유도된 α,β-불포화 아미드계 화합물
CN102119162B (zh) 二氮杂咔唑及其使用方法
TWI448465B (zh) 乙炔基衍生物
CN106456582A (zh) TrkA 激酶抑制剂、组合物及其方法
JP2016501251A (ja) がんの治療のための新規二環フェニル−ピリジン／ピラジン
WO2015075665A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN115768757B (zh) Cd206调节剂及其用途和制备方法
CN111655689B (zh) 吡唑并吡啶酮化合物
CN116891464A (zh) 一种at2r激动剂
TW202515544A (zh) 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物
RS65335B1 (sr) Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
TW202214634A (zh) 雜環化合物及其衍生物
CN119143752A (zh) 氨基喹啉衍生物、包含其的药物组合物及其制备方法和用途
US8410279B2 (en) Substituted pyrroles and methods of use
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
CN121985945A (en) Pharmaceutical compounds and compositions as inhibitors of c-KIT kinase
HK40045062B (en) Pyrazine compounds and uses thereof
HK40037929B (en) Pyrazine compounds and uses thereof
HK40037929A (en) Pyrazine compounds and uses thereof
HK40063823B (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HK40046602A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof